Shigella sonnei antigens (S. sonnei antigens)

Shigella sonnei antigens are the primary molecular determinants of pathogenicity and the central targets for immunotherapeutic and prophylactic interventions against shigellosis, a leading cause of bacterial dysentery worldwide [1]. The most critical target is the O-specific polysaccharide (O-antigen), a unique carbohydrate structure within the bacterial lipopolysaccharide (LPS) that defines the S. sonnei serotype and is essential for bacterial survival in the host environment [2]. Unlike other Shigella species, S. sonnei exists as a single serotype, making its O-antigen an ideal candidate for vaccine-induced broad protection [3]. Other key antigens include the invasion plasmid antigens (Ipa proteins, such as IpaB and IpaC), which are essential components of the Type III secretion system (T3SS) used by the bacterium to facilitate the invasion of colonic epithelial cells [4]. Current therapeutic strategies focus on bioconjugate vaccines, Generalized Modules for Membrane Antigens (GMMA), and monoclonal antibodies that aim to elicit robust anti-O-antigen IgG and IgA responses to neutralize the bacteria and prevent mucosal colonization [5][6]. Targeting these antigens is a critical priority for addressing the increasing global burden of antibiotic-resistant Shigella infections [7].

Other names

Shigella sonnei O-antigenS. sonnei O-specific polysaccharideS. sonnei lipopolysaccharideInvasion plasmid antigens (Ipa proteins)Shigella sonnei Type III secretion system (T3SS) antigensS. sonnei LPS

Induction of antigen-specific humoral and mucosal immunity (IgG and IgA) to neutralize bacterial virulence factors, inhibit epithelial cell invasion, and facilitate immune-mediated clearance of the pathogen.